ZD 6021

Known as: (3-cyano-N-(2-(3,4-dichlorophenyl)-4-(4-(2-(methylsulfinyl)phenyl)piperidino)butyl)-N-methyl)naphthamide, ZD-6021, ZD6021 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2009
01220012009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Tachykinin NK receptors (NKRs) differ to a large degree among species with respect to their affinities for small molecule… (More)
Is this relevant?
2008
2008
Tachykinin NK(2) receptor antagonists are potentially beneficial in treating various disorders including irritable bowel syndrome… (More)
Is this relevant?
2007
2007
We compared the neurokinin 1 receptor (NK(1)R) antagonists aprepitant, CP-99994 [(2S,3S)-3-(2-methoxybenzylamino)-2… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Is this relevant?
2007
2007
The present study investigates the pharmacology of the cloned neurokinin 1 receptor from the gerbil (gNK(1)R), a species claimed… (More)
Is this relevant?
2004
2004
This study assessed the involvement of NMDA and group I metabotropic glutamate receptors, and tachykinin NK1 and NK3 receptors… (More)
Is this relevant?
2002
2002
Through optimization of compounds based on the dual NK(1)/NK(2) antagonist ZD6021, it was found that alteration of two key… (More)
Is this relevant?
2001
2001
The tachykinins, substance P, neurokinin A, and neurokinin B, have been implicated in many diseases. The present study evaluated… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?
2001
2001
Exploration of the SAR around selective NK2 antagonists, SR48968 and ZD7944, led to the discovery that naphth-1-amide analogues… (More)
Is this relevant?